SCHEMBL7897372

SCHEMBL7897372

CO/N=C1\CCc2c(F)cccc21

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SRD5A1 P18405 1/20 0.39
CYP19A1 P11511 2/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
TYMS P04818 1/20 0.35
NR3C1 P04150 1/20 0.34
DRD2 P14416 4/20 0.33
DRD3 P35462 4/20 0.33
HTR1A P08908 3/20 0.33
HTR7 P34969 3/20 0.33
MAPT P10636 2/20 0.32
ALDH1A1 P00352 2/20 0.32
KMT2A Q03164 2/20 0.32
GSK3A P49840 1/20 0.32
GSK3B P49841 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
KDM4E B2RXH2 1/20 0.31
NOTUM Q6P988 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL159742 1.00 SRD5A1 (0.39) SRD5A1CYP19A1CYP11B1CYP11B2TYMS
SCHEMBL27873730 1.00 SRD5A1 (0.39) SRD5A1CYP19A1CYP11B1CYP11B2TYMS
SCHEMBL17190969 0.81 PARP1 (0.41) CYP19A1CYP11B1CYP11B2TYMSMAPT
SCHEMBL7897504 0.79 KDM4E (0.31) MAPTKDM4E
SCHEMBL168071 0.79 PARP10 (0.40) MAPTKDM4E
SCHEMBL27873727 0.79 PARP10 (0.40) MAPTKDM4E
SCHEMBL1857350 0.79 PARP10 (0.40) MAPTKDM4E
SCHEMBL5465899 0.77
SCHEMBL7897374 0.77 MAPT (0.35) HTR1AMAPTKDM4E
SCHEMBL158376 0.77 MAPT (0.35) HTR1AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252957-A1 PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS ELAN PHARMACEUTICALS, INC. (US) 2013-09-26 US disclosed
US-20130252957-A1 PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS ELAN PHARMACEUTICALS, INC. (US) 2013-09-26 US disclosed
US-8367836-B2 Pyridinone antagonists of alpha-4 integrins ELAN PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-20110009407-A1 PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS ELAN PHARMACEUTICALS, INC. 2011-01-13 US disclosed
US-20110009407-A1 PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS ELAN PHARMACEUTICALS, INC. 2011-01-13 US disclosed
WO-2010126914-A1 PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS ELAN PHARMACEUTICALS, INC. (US) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252957-A1 PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS ITGA4, ITGB4, ITGB5 SRD5A1 1405/4885CYP19A1 4831/4885CYP11B1 2942/4885
US-20110009407-A1 PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS ITGA4, ITGB4, ITGB5 SRD5A1 1405/4885CYP19A1 4831/4885CYP11B1 2942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.